ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: FR-PO1107

Safety and Efficacy of One and Two Booster Doses of SARS-CoV-2 mRNA Vaccines in Kidney Transplant Recipients: A Randomized Clinical Trial

Session Information

  • COVID-19 - II
    November 03, 2023 | Location: Exhibit Hall, Pennsylvania Convention Center
    Abstract Time: 10:00 AM - 12:00 PM

Category: Coronavirus (COVID-19)

  • 000 Coronavirus (COVID-19)

Authors

  • Drenko, Petr, Department of Internal Medicine I, Faculty of Medicine in Pilsen, Charles University, and University Hospital, Pilsen, Czechia
  • Kacer, Martin, Department of Internal Medicine I, Faculty of Medicine in Pilsen, Charles University, and University Hospital, Pilsen, Czechia
  • Kielberger, Lukas, Department of Internal Medicine I, Faculty of Medicine in Pilsen, Charles University, and University Hospital, Pilsen, Czechia
  • Vlas, Tomas, Department of Immunology and Allergology, Faculty of Medicine in Pilsen, Charles University, and University Hospital, Pilsen, Czechia
  • Kucera, Radek, Department of Immunochemistry Diagnostics, Faculty of Medicine in Pilsen, Charles University, and University Hospital, Pilsen, Czechia
  • Reischig, Tomas, Department of Internal Medicine I, Faculty of Medicine in Pilsen, Charles University, and University Hospital, Pilsen, Czechia
Background

Kidney transplant recipients are at risk for a severe course of COVID-19 with a high mortality rate. Although an adequate humoral response to COVID-19 vaccination is therefore essential, a considerable number of patients remains without a satisfactory serological response after the baseline and adjuvant SARS-CoV-2 vaccination schedule.

Methods

In this prospective, randomized study, we evaluated the efficacy and safety of one and two booster doses of mRNA vaccines (either mRNA-1273 or BNT162b2) in 125 COVID-19 naive, adult kidney transplant recipients who showed an insufficient humoral response (SARS-CoV-2 IgG <10 AU/ml) to the previous 2-dose vaccination schedule. The primary outcome was the occurrence of a positive antibody response between one and two booster doses at one month after the final booster dose.

Results

A positive humoral response was observed in 36 (62%) patients who received two booster doses and in 28 (44%) patients who received one booster dose (p=.043). Moreover, median SARS-CoV-2 IgG levels were higher with two booster doses (p=.009). The number of patients with positive virus neutralizing antibody levels was numerically higher in the two booster doses compared to the single booster dose, but without statistical significant (66% vs. 50%, p=.084). There was no significant difference in the rate of positive seroconversion and antibody levels between mRNA-1273 and BNT162b2 vaccines.

Conclusion

A higher number of kidney transplant recipients achieved a positive antibody response after two booster doses compared to one booster dose.

Funding

  • Other NIH Support